|
AML drug begins phase II trials |
A phase II clinical trial of a new acute myeloid leukaemia (AML) drug designed for elderly patients has been initiated.
Cyclacel Pharmaceuticals said that oral sapacitabine is being studied to determine the survival rates of patients who have not been treated for the disease, or are experiencing their first relapse, when they are given one of three different doses of the drug. |
|
Read more...
|
|
|
Phase II trials of diabetic ulcer drug launch |
Phase II trials of a topical drug designed to treat diabetic foot ulcers have begun, it has been announced.
Innocoll revealed that CollaRx Gentamicin Topical, which is designed to deliver a powerful dose of antibiotic to the infected area, is to undergo a total of three separate phase II tests. |
|
Read more...
|
|
|
MMD drug gets orphan designation |
The US Food and Drug Administration has given a new drug designed to treat patients with Myotonic Muscular Dystrophy (MMD) orphan drug designation, it has been announced.
Drug firm Insmed said that Iplex had been given the nod from the body as the drug continues to undergo a 24-week phase III enabling trial in patients suffering from MMD. |
|
Read more...
|
|
|
ACS drug gets orphan designation |
A respiratory drug currently undergoing phase II clinical trials in the US has been awarded orphan drug designation from the country's Food and Drug Administration.
Anthera Pharmaceuticals announced that A-001, which is being studied for is effectiveness in preventing acute chest syndrome (ACS) in patients living with blood disorder sickle cell disease (SCD), also won approval for use in expanded tests. |
|
Read more...
|
|
|
Cancer drug gets EU orphan designation |
A new cancer drug has been granted orphan drug status by the European Medicines Agency (EMEA).
AstraZeneca revealed that AZD2281, which it acquired when it purchased Kudos Pharmaceuticals last year, had received the nod from the EMEA, giving it special benefits during the development process and the right to claim market exclusivity in the years following full approval. |
|
Read more...
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 Next > End >>
|
| Results 10 - 18 of 47 |